Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain.
H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Madrid, 28029, Spain.
Future Oncol. 2021 Jun;17(18):2279-2289. doi: 10.2217/fon-2020-1212. Epub 2021 Mar 19.
Lurbinectedin is a marine-derived drug that inhibits transcription, a process that is frequently dysregulated in small cell lung cancer. The activity of lurbinectedin has been studied in many solid tumors, showing not only promising results but also a favorable safety profile. In relapsed small cell lung cancer, the drug has shown encouraging activity both as a single agent and in combination with doxorubicin, paclitaxel or irinotecan. The USA FDA has recently granted accelerated approval to lurbinectedin monotherapy in this setting. This article provides an update on available data and ongoing studies of lurbinectedin in small cell lung cancer, including Phase I combination trials, the basket Phase II trial and the ATLANTIS Phase III trial.
鲁比卡丁是一种海洋来源的药物，可抑制转录，这一过程在小细胞肺癌中经常失调。鲁比卡丁已在许多实体瘤中进行了研究，不仅显示出有希望的结果，而且具有良好的安全性。在复发性小细胞肺癌中，该药物作为单一药物以及与多柔比星、紫杉醇或伊立替康联合使用均显示出令人鼓舞的活性。美国 FDA 最近加速批准了该药在这一适应证中的单药治疗。本文提供了小细胞肺癌中鲁比卡丁的现有数据和正在进行的研究的最新信息，包括 I 期联合试验、篮子Ⅱ期试验和 ATLANTIS Ⅲ期试验。
